NLRP3 and COVID-19: Pirfenidone, an approved drug for the treatment of idiopathic pulmonary fibrosis, could inhibit the assembly of NLRP3 inflammasome and alleviate lung inflammation and the duration of hospital stay in COVID-19 patients (202).